Board of Directors Lipum
Dr Ingemar Kihlström, Chairman Of The Board
Born: 1952 | Entered: 2021
Total shares with related parties and insurance: 0
Warrants B2 2021/2025: 7 500
Dr Ingemar Kihlström has doctoral degree in physiology/toxicology from Uppsala University. He has extensive experience in drug development and the Life Science industry. Previously Dr Kihlström worked with research and development and business development at both Astra AB and Pharmacia AB followed by a career as pharmaceutical analyst in the finance industry at Swedbank, Aros Securities and ABG Sundal Collier. Over the years, he has worked both as Chairman and Director on the board of more than thirty companies and Dr Kihlström is currently on the board of several listed companies, mainly on Nasdaq First North in Stockholm. Independent in relation to the company, the management and major shareholders.
Professor Olle Hernell, Board Member and Co-Founder
Born: 1945 | Entered: 2010
Total shares with related parties and insurance: 341 369
Warrants B2 2021/2025: 0
Olle Hernell, MD, PhD, Professor of pediatrics and former head of Pediatrics at the Department of Clinical Sciences, Umeå University. He has more than 30 year experience as senior consultant, responsible for pediatric gastroenterology, hepatology and nutrition. He discovered the bile salt-stimulated lipase (BSSL) in human milk and is internationally well known for his BSSL research, clarifying its structure, characteristics and physiological function in fat digestion and its role in inflammation. Prof. Hernell´s research spans from basic science to clinical trials, including a recent phase III RCT conducted by Swedish Orphan Biovitrum (Sobi). He has published close to 300 peer reviewed scientific papers, trained more 20 PhD students, served on/or chaired many national and international committees and working groups. He is an inventor on several patents and has long experience of collaboration with industry. Dependent in relation to the company, the management and major shareholders.
Dr. Kristian Sandberg, Board Member
Born: 1961 | Entered: 2020
Total shares with related parties and insurance: 0
Warrants B2 2021/2025: 7 500
PhD in Immunology from SLU Uppsala. Kristian Sandberg has over 20 years of experience from AstraZeneca in various roles within research and development, primarily with project management responsibilities. He has experience in the development of both biological and conventional drugs from concept to clinical phase II studies in the areas of neuroscience as well as respiratory, inflammatory, and autoimmune diseases. Since 2015, Kristian Sandberg has been the director of the Drug Discovery and Development Platform (DDD) at SciLifeLab, Uppsala University. He has been a board member of Toleranzia AB since 2017 and has been affiliated with Karolinska Institutet since 2012. Independent of the company, management, and major shareholders.
Åsa Hansdotter, Board Member
Born: 1974 | Entered: 2021
Total shares with related parties and insurance: 0
Warrants B2 2021/2025: 0
Åsa Hansdotter is an attorney-at-law and partner of the business law firm HWF Advokater AB in Helsingborg. She works with company and equity capital markets law, Swedish and international M&A and further handles corporate commercial matters as external legal counsel for listed and non-listed companies within the industry and life science sectors among others. During 2001-2017, Åsa was with Mannheimer Swartling, 2010-2017 as a partner. Åsa is a board member in i.a. Dizlin Pharmaceuticals AB, P Capital Partners AB and the Swedish Chamber of Commerce for Russia & CIS. Independent in relation to the company, the management and major shareholders.
Dr Carl-Johan Spak, Board Member
Born: 1956 | Entered: 2023
Total shares with related parties and insurance: 3 500
Warrants B2 2021/2025: 0
Carl-Johan Spak is a senior advisor at Flerie Invest AB. Carl-Johan held senior positions at Recipharm between 2009 and April 2021, prior to which he was Head of Meda’s Nordic organisation and CEO of Recip AB. He is currently engaged as a board member in several life science companies, both in Sweden and internationally. Carl-Johan has a degree in dentistry and a PhD in cariology and pharmacology from Karolinska Institute. Among his board assignments are XSpray Pharma AB, Atrogi AB, EpiEndo ehf, Symcel Sverige AB and Buzzard Pharmaceuticals AB. Independent in relation to the company, company management and major shareholders.
Åsa Magnusson, Board Member
Born: 1966 | Entered: 2024
Total shares with related parties and insurance: 0
Warrants B2 2021/2025: 0
Åsa Magnusson has a Bachelor of Business Administration and B2B Marketing from Lund University. She is a senior executive with long international commercial experience in the life science industry in both publicly listed and privately owned biotech and pharma companies. She has a proven track record of leading cross-functional teams at Arvelle, Alexion and Actelion, preparing for and launching high value medicines by securing market access to specialist and orphan drugs in competitive markets. In her current role as Chief Engagement & Commercial Officer (CCO) at Vicore Pharma, Åsa leverages her expertise and network within a research-intensive organization, to develop a clear go-to-market strategy essential for realizing the value of pipeline assets.